Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01265836

Acronym

DEMAND

Enrollment

1064

Registered

2010-12-23

Start date

2011-03-31

Completion date

2013-03-31

Last updated

2011-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Keywords

Dyslipidemia Treatment and Cardiovascular Outcomes

Brief summary

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Detailed description

MC MD

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Provision of subject informed consent, Female or male aged = 18 years * Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

Exclusion criteria

* Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site). * Previous enrolment or randomisation of treatment in the present study * Participation in a clinical study during the last 90 days

Design outcomes

Primary

Measure	Time frame
The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.	1 year
The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.	1 year

Secondary

Measure	Time frame
The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year	1 year
The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets	1 year
The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets	1 year
The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year	1 year
The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1	1 year
The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1	1 year

Outcome results